Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InspireMD (NSPR) Accounts Payables (2016 - 2025)

Historic Accounts Payables for InspireMD (NSPR) over the last 16 years, with Q3 2025 value amounting to $9.1 million.

  • InspireMD's Accounts Payables rose 5206.38% to $9.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.1 million, marking a year-over-year increase of 5206.38%. This contributed to the annual value of $6.4 million for FY2024, which is 2643.18% up from last year.
  • InspireMD's Accounts Payables amounted to $9.1 million in Q3 2025, which was up 5206.38% from $7.6 million recorded in Q2 2025.
  • In the past 5 years, InspireMD's Accounts Payables registered a high of $9.1 million during Q3 2025, and its lowest value of $2.5 million during Q1 2021.
  • Moreover, its 5-year median value for Accounts Payables was $4.1 million (2023), whereas its average is $4.6 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first crashed by 43.24% in 2021, then surged by 5206.38% in 2025.
  • Over the past 5 years, InspireMD's Accounts Payables (Quarter) stood at $3.5 million in 2021, then grew by 27.71% to $4.4 million in 2022, then increased by 15.19% to $5.1 million in 2023, then grew by 26.43% to $6.4 million in 2024, then surged by 41.08% to $9.1 million in 2025.
  • Its last three reported values are $9.1 million in Q3 2025, $7.6 million for Q2 2025, and $5.6 million during Q1 2025.